Each drug is counted once, at the furthest phase among its ongoing PD-1 or PD-L1 trials. Trials registered as phase 1/2 get their own bar; phase 2/3 trials count as phase 3. Select a bar to filter the table.
Number of different new drugs aimed at each target. It leaves out undisclosed targets, new PD-1 and PD-L1 antibodies (the backbone the other drugs are added to), and personalized neoantigen vaccines and oncolytic viruses, which share an approach rather than a target.
New drugs being tested in each cancer type, split by the furthest phase each drug has reached in that cancer. A drug can count under several cancers; trials open to many tumor types count as basket trials. Select a bar to filter the table.
Ongoing PD-1 or PD-L1 trials that test at least one of these new drugs, by the cancer types each trial lists and split by the trial's phase. A trial can count under several cancers; trials open to many tumor types count as basket trials. Select a bar to filter the table.
—
| Cancer types | Example trial |
|---|